Market capitalization | $76.31m |
Enterprise Value | $-54.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 2.28 |
P/B ratio (TTM) P/B ratio | 0.59 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-33.88m |
Free Cash Flow (TTM) Free Cash Flow | $-23.75m |
Cash position | $130.69m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
4 Analysts have issued a ESSA Pharma Inc forecast:
4 Analysts have issued a ESSA Pharma Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.10 -0.10 |
17%
17%
|
|
EBITDA | -34 -34 |
6%
6%
|
EBIT (Operating Income) EBIT | -34 -34 |
6%
6%
|
Net Profit | -28 -28 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
Head office | Canada |
CEO | David Parkinson |
Employees | 50 |
Founded | 2009 |
Website | www.essapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.